Abeona Therapeutics Inc (NASDAQ:ABEO) Stake Trimmed by Rosalind Advisors Inc.

Rosalind Advisors Inc. reduced its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 1.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,805,390 shares of the biopharmaceutical company’s stock after selling 26,610 shares during the period. Abeona Therapeutics comprises 5.0% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 6th biggest position. Rosalind Advisors Inc.’s holdings in Abeona Therapeutics were worth $10,056,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. purchased a new stake in Abeona Therapeutics in the 3rd quarter worth about $151,000. Citigroup Inc. boosted its position in Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares during the period. Western Standard LLC boosted its position in Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after purchasing an additional 110,998 shares during the period. Jane Street Group LLC purchased a new position in shares of Abeona Therapeutics in the third quarter worth about $84,000. Finally, XTX Topco Ltd purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at approximately $160,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Stock Performance

NASDAQ:ABEO opened at $5.15 on Friday. The business has a 50 day moving average price of $5.44 and a 200-day moving average price of $5.83. Abeona Therapeutics Inc has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The firm has a market cap of $223.88 million, a PE ratio of -1.91 and a beta of 1.79.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.19. Equities research analysts predict that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Oppenheimer began coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective for the company. StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.